The role of positron emission tomography (PET) in the management of lymphoma patients

Annals of Oncology

Volumn 10, Issue 10, 1999, Pages 1181-1184

  Zinzani, P L ^a   Magagnoli, M ^b   Chierichetti, F ^b   Zompatori, M ^b   Garraffa, G ^b   Bendandi, M ^b   Gherlinzoni, F ^b   Cellini, C ^b   Stefoni, V ^b   Ferlin, G ^b   Tura, S ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Abdominal mass; Aggressive NHL; CT scan; HD; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; FIBROSIS; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ABDOMEN; ADOLESCENT; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROSIS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOGRAPHY, ABDOMINAL; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032738030     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008327127033     Document Type: Article

References (28)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Tura S, Canellos GP, Goldstone A et al. Hodgkin's disease: Controversies and challenges for the future. Haematologica 1991; 76: 63-79.
3. Canellos GP, Nadler L, Tavkorian T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin Hematol 1988; 25: 58-65.
4. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-7.
5. Salloum E, Scwab Brandt D, Caride VJ et al. Gallium scans in the management of patients with Hodgkin's disease: A study of 101 patients. J Clin Oncol 1997; 15: 518-27.
6. Zinzani PL, Zompatori M, Bendandi M et al. Monitoring bulky mediastinal disease with Gallium-67, CT scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymph 1996; 22: 131-5.
7. Setoian FJ, Pons F, Herranz R et al. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun 1997; 18: 405-11.
8. Gasparini M, Bombardieri E, Castellani M et al. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 1998; 39: 1586-90.
9. Bendini M, Zuiani C, Bazzocchi M et al. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant: A prospective pilot study. MAGMA 1996; 4: 213-24.
10. Zinzani PL, Magagnoli M, Franchi R et al. Prognostic role of Gallium scan in the management of lymphoma with mediastinal involvement. Haematologica (in press).
11. 11C] methionine in asessment of response in non-Hodgkin lymphoma. Lancet 1990; i: 1188.
12. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-8.
13. Stumpe KDM, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
14. Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: Detection with FDG-PET versus CT. Radiology 1998; 206: 475-81.
15. 18F]fluoro2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-22.
16. Carr R, Barrington SF, Madan B et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-6.
17. Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-71.
18. Kotzerke J, Guhlmann A, Moog Florian et al. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26: 31-8.
19. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Comm 1999; 20: 13-20.
20. de Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (Suppl 1): S57-60.
21. Som P, Atkins HL, Bandophadhyah D. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18). J Nucl Med 1980; 21: 670-5.
22. Warbur O. On the origin of cancer cells. Science 1956; 123: 309-14.
23. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
24. Bonadonna G, Zucali R, De Lena P et al. Combinated chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep 1977; 61: 769-77.
25. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
26. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457-81.
27. Mantel H, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959; 22: 719-48.
28. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-91.